glp-1 appetite suppression for Weight Loss and Diabetes Mechanisms of GLP-1 Receptor Agonist-Induced

Between 2025 and 2030, the global pharmaceutical industry faces a Loss of Exclusivity (LOE) wave that puts an estimated $200 billion to $400 billion in branded drug revenue at direct risk.

A weight-loss pill that works

Interestingly, kinome analysis of mouse islets demonstrated that an acute treatment with exendin 4 increased pRb phosphorylation and subsequent E2f1 transcriptional activity

Comprehensive Metabolic Health & Fat Metabolism Support

Full article linked below.

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that it helped people lower their weight by an average of 12% after 72 weeks.